BindingDB logo
myBDB logout

109 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27190600 48 Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.EBI Merck Research Laboratories
27106708 130 The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.EBI Merck Research Laboratories
25147615 108 Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes.EBI XuanZhu Pharma
25164763 95 Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.EBI Shanghai Institute of Materia Medica
26005541 33 Design, Synthesis, and Pharmacological Evaluation of Fused▀-Homophenylalanine Derivatives as Potent DPP-4 Inhibitors.EBI Chinese Academy of Sciences
25457126 55 (R)-3-amino-1-((3aS,7aS)-octahydro-1H-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: design, synthesis, biological evaluation, and molecular modeling.EBI Chinese Academy of Sciences
24660890 12 Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.EBI Merck & Co., Inc.
24531224 30 Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.EBI Shenyang Pharmaceutical University
24439847 24 Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.EBI Novartis Institutes for BioMedical Research
24153396 97 Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.EBI Chinese Academy of Sciences
23964740 68 Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).EBI Bristol-Myers Squibb
23994324 28 Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.EBI First Affiliated Hospital of Guangzhou Medical University
23972441 40 Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (23).EBI Merck Research Laboratories
23938053 36 Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.EBI Zhejiang University
23594271 68 Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.EBI Tufts University Sackler School of Biomedical Sciences
17462890 4 Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors.EBI Korea Research Institute of Chemical Technology
23072865 59 Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors.EBI Toray Industries, Inc.
23025999 33 Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.EBI Takeda California
22959556 57 Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.EBI Mitsubishi Tanabe Pharma Corporation
22938786 86 Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.EBI Dainippon Sumitomo Pharma Co., Ltd
22853995 57 4-Substituted boro-proline dipeptides: synthesis, characterization, and dipeptidyl peptidase IV, 8, and 9 activities.EBI Tufts University School of Medicine
22824762 39 Fused bicyclic heteroarylpiperazine-substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group.EBI Mitsubishi Tanabe Pharma Corporation
22475866 19 Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.EBI Chinese Academy of Sciences
22377519 23 An example of designed multiple ligands spanning protein classes: dual MCH-1R antagonists/DPPIV inhibitors.EBI Prosidion Ltd
21218817 52 Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor.EBI Takeda Pharmaceutical Company Limited
21106276 18 The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.EBI Chinese Academy of Sciences
20718420 167 Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.EBI National Health Research Institutes
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
19375196 22 Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.EBI Sichuan University
19217790 68 Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.EBI Matrix Laboratories Limited
18346892 42 Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.EBI Takeda San Diego
17962025 24 Discovery of long-acting N-(cyanomethyl)-N-alkyl-L-prolinamide inhibitors of dipeptidyl peptidase IV.EBI Minase Research Institute
18201067 276 Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.EBI Merck Research Laboratories
17869513 112 Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes.EBI Merck Research Laboratories
17331715 19 Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors.EBI Korea Research Institute of Chemical Technology
17822893 61 (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.EBI Pfizer Global Research and Development
17113301 83 Lead optimization of [(S)-gamma-(arylamino)prolyl]thiazolidine focused on gamma-substituent: Indoline compounds as potent DPP-IV inhibitors.EBI Mitsubishi Pharma Corporation
22019046 35 Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.EBI Sanwa Kagaku Kenkyusho Co. Ltd
21996520 149 7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.EBI Bristol-Myers Squibb Research and Development
21865048 29 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.EBI Dainippon Sumitomo Pharma Co. Ltd
21711053 106 Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?EBI University of Antwerp (UA)
21741847 20 Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.EBI Takeda Pharmaceutical Company Limited
21478015 6 Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-relateda-glucosidase inhibitors and liver X receptor antagonists.EBI The University of Tokyo
24900243 44 Design, Synthesis, and in Vitro Evaluation of Novel Aminomethyl-pyridines as DPP-4 Inhibitors.EBI TBA
21324688 36 1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.EBI Pfizer Inc.
21320777 375 Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors.EBI Merck Research Laboratories
21306895 46 Discovery ofß-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.EBI Korea Research Institute of Chemical Technology
21186796 83 Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.EBI Takeda San Diego, Inc.
21163664 24 Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125.EBI Takeda Pharmaceutical Company Limited
21074430 53 Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.EBI Dainippon Sumitomo Pharma Co., Ltd
20833042 51 Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors.EBI Bristol-Myers Squibb Research and Development
20684603 101 Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.EBI Bristol-Myers Squibb
20598534 105 Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.EBI Bristol-Myers Squibb
20488704 28 Synthesis and biological evaluation of bicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.EBI Shanghai Hengrui Pharmaceuticals Co., Ltd
20488702 21 Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.EBI Shanghai Hengrui Pharmaceuticals Co., Ltd
20483603 106 (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.EBI National Health Research Institutes
19643608 58 Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.EBI Torrent Pharmaceuticals Ltd.
19833514 104 The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements.EBI Santhera Pharmaceuticals (Switzerland) Ltd
19576767 142 From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV.EBI Santhera Pharmaceuticals (Switzerland) Ltd
19539471 130 Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors.EBI Merck& Co. Inc.
19515557 47 Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV.EBI Santhera Pharmaceuticals (Switzerland) Ltd
19275964 64 (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.EBI Pfizer Global Research & Development
19269819 102 Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.EBI National Health Research Institutes
19261480 113 Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.EBI National Health Research Institutes
18996694 30 Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors.EBI Korea Research Institute of Chemical Technology
18783201 27 Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.EBI Tufts University
18602260 177 Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors.EBI Ranbaxy Research Laboratories
18556199 234 Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.EBI University of Antwerp
18556198 125 Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors.EBI University of Antwerp
18524582 52 Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design.EBI Merck Research Laboratories
17977724 83 Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors.EBI Pfizer Global Research and Development
17958345 75 Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates.EBI University of Antwerp
17851076 77 4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV.EBI Merck Research Laboratories
17827003 68 Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors.EBI Merck Research Laboratories
17562364 150 Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors.EBI Merck Research Laboratories
17544668 55 Synthesis, SAR, and X-ray structure of novel potent DPPIV inhibitors: oxadiazolyl ketones.EBI LG Life Sciences, Ltd
17502141 25 Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors.EBI Merck Research Laboratories
17434732 99 Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate).EBI Merck Research Laboratories
17433672 16 Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.EBI Merck Research Laboratories
17194587 106 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.EBI National Health Research Institutes
17055271 18 Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor.EBI Tufts University School of Medicine
16844373 25 Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines.EBI Laboratory of Medicinal Chemistry University of Antwerp
16722626 94 cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.EBI Pfizer Global Research and Development
16084722 55 Boro-norleucine as a P1 residue for the design of selective and potent DPP7 inhibitors.EBI ActivX Biosciences
15927466 52 Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors.EBI National Health Research Institutes
15380217 87 Potent and selective proline derived dipeptidyl peptidase IV inhibitors.EBI Merck & Co. Inc.
9195869 28 Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes.BDB Laboratorium für Organische Chemie
20017516 11 Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain.BDB Stanford University
19450983 74 Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.BDB Universite degli Studi di Firenze
17616632 11 Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.BDB NIH
18760609 66 Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.BDB Philipps-University Marburg
19630403 19 Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia (dagger) dagger Coordinates of the PDE10A crystal structures have been depoBDB Pfizer
19422229 125 Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.BDB Novartis
19328688 12 Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.BDB Roche R&D Center(China) Ltd
19348415 52 Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IkappaB kinase-beta (IKK-beta).BDB GSK
19143533 44 Discovery and Structure-Activity Relationships of Trisubstituted Pyrimidines/Pyridines as Novel Calcium-Sensing Receptor Antagonists.BDB Bristol-Myers Squibb Company
19256504 18 Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.BDB AstraZeneca
19193011 49 Pyrido[2,3-d]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors (dagger).BDB Johnson & Johnson Pharmaceutical
19056263 34 Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase.BDB GSK